Read by QxMD icon Read


shared collection
16 papers 25 to 100 followers
By Venkatesh Ariyamuthu Transplant Nephrologist at UT Southwestern Medical Center
Godela M Brosnahan, Kaleab Z Abebe, Charity G Moore, Frederic F Rahbari-Oskoui, Kyongtae T Bae, Jared J Grantham, Robert W Schrier, William E Braun, Arlene B Chapman, Michael F Flessner, Peter C Harris, Marie C Hogan, Ronald D Perrone, Dana C Miskulin, Theodore I Steinman, Vicente E Torres
BACKGROUND: Previous clinical studies of autosomal dominant polycystic kidney disease (ADPKD) reported that loss of kidney function usually follows a steep and relentless course. A detailed examination of individual patterns of decline in estimated glomerular filtration rate (eGFR) has not been performed. STUDY DESIGN: Longitudinal post hoc analysis of data collected during the Halt Progression of Polycystic Kidney Disease (HALT-PKD) trials. SETTING & PARTICIPANTS: 494 HALT-PKD Study A participants (younger; preserved eGFR) and 435 Study B participants (older; reduced eGFR) who had more than 3 years of follow-up and 7 or more eGFR assessments...
May 2018: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
Wouter N Leonhard, Hester Happe, Dorien J M Peters
Patients with autosomal dominant polycystic kidney disease (ADPKD) typically carry a mutation in either the PKD1 or PKD2 gene, which leads to massive cyst formation in both kidneys. However, the large intrafamilial variation in the progression rate of ADPKD suggests involvement of additional factors other than the type of mutation. The identification of these factors will increase our understanding of ADPKD and could ultimately help in the development of a clinically relevant therapy. Our review addresses the mechanisms by which various biologic processes influence cyst formation and cyst growth, thereby explaining an important part of the inter- and intrafamilial variability in ADPKD...
December 2016: Journal of the American Society of Nephrology: JASN
Youngwoo Kim, Yinghui Ge, Cheng Tao, Jianbing Zhu, Arlene B Chapman, Vicente E Torres, Alan S L Yu, Michal Mrug, William M Bennett, Michael F Flessner, Doug P Landsittel, Kyongtae T Bae
BACKGROUND AND OBJECTIVES: Our study developed a fully automated method for segmentation and volumetric measurements of kidneys from magnetic resonance images in patients with autosomal dominant polycystic kidney disease and assessed the performance of the automated method with the reference manual segmentation method. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Study patients were selected from the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease...
April 7, 2016: Clinical Journal of the American Society of Nephrology: CJASN
Jacob A Akoh
Autosomal dominant polycystic kidney disease (ADPKD), the most frequent cause of genetic renal disease affecting approximately 4 to 7 million individuals worldwide and accounting for 7%-15% of patients on renal replacement therapy, is a systemic disorder mainly involving the kidney but cysts can also occur in other organs such as the liver, pancreas, arachnoid membrane and seminal vesicles. Though computed tomography and magnetic resonance imaging (MRI) were similar in evaluating 81% of cystic lesions of the kidney, MRI may depict septa, wall thickening or enhancement leading to upgrade in cyst classification that can affect management...
September 6, 2015: World Journal of Nephrology
Cheng Xue, Chenchen Zhou, Bing Dai, Shengqiang Yu, Chenggang Xu, Zhiguo Mao, Chaoyang Ye, Dongping Chen, Xuezhi Zhao, Jun Wu, Wansheng Chen, Changlin Mei
BACKGROUND: Blood pressure (BP) control is one of the most important treatments of Autosomal dominant polycystic kidney disease (ADPKD). The comparative efficacy of antihypertensive treatments in ADPKD patients is inconclusive. METHODS: Network meta-analysis was used to evaluate randomized controlled trials (RCT) which investigated antihypertensive treatments in ADPKD. PubMed, Embase, Ovid, and Cochrane Collaboration were searched. The primary outcome was estimated glomerular filtration rate (eGFR)...
December 15, 2015: Oncotarget
Fouad T Chebib, Vicente E Torres
No abstract text is available yet for this article.
May 2016: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
Sajeda Youssouf, Tess Harris, Donal O'Donoghue
No abstract text is available yet for this article.
May 2015: Nephrology, Dialysis, Transplantation
Arlene B Chapman, Olivier Devuyst, Kai-Uwe Eckardt, Ron T Gansevoort, Tess Harris, Shigeo Horie, Bertram L Kasiske, Dwight Odland, York Pei, Ronald D Perrone, Yves Pirson, Robert W Schrier, Roser Torra, Vicente E Torres, Terry Watnick, David C Wheeler
Autosomal-dominant polycystic kidney disease (ADPKD) affects up to 12 million individuals and is the fourth most common cause for renal replacement therapy worldwide. There have been many recent advances in the understanding of its molecular genetics and biology, and in the diagnosis and management of its manifestations. Yet, diagnosis, evaluation, prevention, and treatment vary widely and there are no broadly accepted practice guidelines. Barriers to translation of basic science breakthroughs to clinical care exist, with considerable heterogeneity across countries...
July 2015: Kidney International
María V Irazabal, Laureano J Rangel, Eric J Bergstralh, Sara L Osborn, Amber J Harmon, Jamie L Sundsbak, Kyongtae T Bae, Arlene B Chapman, Jared J Grantham, Michal Mrug, Marie C Hogan, Ziad M El-Zoghby, Peter C Harris, Bradley J Erickson, Bernard F King, Vicente E Torres
The rate of renal disease progression varies widely among patients with autosomal dominant polycystic kidney disease (ADPKD), necessitating optimal patient selection for enrollment into clinical trials. Patients from the Mayo Clinic Translational PKD Center with ADPKD (n=590) with computed tomography/magnetic resonance images and three or more eGFR measurements over ≥6 months were classified radiologically as typical (n=538) or atypical (n=52). Total kidney volume (TKV) was measured using stereology (TKVs) and ellipsoid equation (TKVe)...
January 2015: Journal of the American Society of Nephrology: JASN
Marie C Hogan, Jason L Bakeberg, Vladimir G Gainullin, Maria V Irazabal, Amber J Harmon, John C Lieske, M Cristine Charlesworth, Kenneth L Johnson, Benjamin J Madden, Roman M Zenka, Daniel J McCormick, Jamie L Sundsbak, Christina M Heyer, Vicente E Torres, Peter C Harris, Christopher J Ward
Autosomal dominant polycystic kidney disease (ADPKD) is a common cause of ESRD. Affected individuals inherit a defective copy of either PKD1 or PKD2, which encode polycystin-1 (PC1) or polycystin-2 (PC2), respectively. PC1 and PC2 are secreted on urinary exosome-like vesicles (ELVs) (100-nm diameter vesicles), in which PC1 is present in a cleaved form and may be complexed with PC2. Here, label-free quantitative proteomic studies of urine ELVs in an initial discovery cohort (13 individuals with PKD1 mutations and 18 normal controls) revealed that of 2008 ELV proteins, 9 (0...
July 2015: Journal of the American Society of Nephrology: JASN
Robert W Schrier, Kaleab Z Abebe, Ronald D Perrone, Vicente E Torres, William E Braun, Theodore I Steinman, Franz T Winklhofer, Godela Brosnahan, Peter G Czarnecki, Marie C Hogan, Dana C Miskulin, Frederic F Rahbari-Oskoui, Jared J Grantham, Peter C Harris, Michael F Flessner, Kyongtae T Bae, Charity G Moore, Arlene B Chapman
BACKGROUND: Hypertension is common in autosomal dominant polycystic kidney disease (ADPKD) and is associated with increased total kidney volume, activation of the renin-angiotensin-aldosterone system, and progression of kidney disease. METHODS: In this double-blind, placebo-controlled trial, we randomly assigned 558 hypertensive participants with ADPKD (15 to 49 years of age, with an estimated glomerular filtration rate [GFR] >60 ml per minute per 1.73 m(2) of body-surface area) to either a standard blood-pressure target (120/70 to 130/80 mm Hg) or a low blood-pressure target (95/60 to 110/75 mm Hg) and to either an angiotensin-converting-enzyme inhibitor (lisinopril) plus an angiotensin-receptor blocker (telmisartan) or lisinopril plus placebo...
December 11, 2014: New England Journal of Medicine
David H Ellison, Julie R Ingelfinger
No abstract text is available yet for this article.
December 11, 2014: New England Journal of Medicine
Roslyn J Simms, Debbie L Travis, Miranda Durkie, Gill Wilson, Ann Dalton, Albert C M Ong
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic cause of renal failure. In most patients who develop end-stage renal disease, transplantation is the renal replacement modality of choice. For living related kidney donation (LRKD), the major challenge is to exclude the diagnosis of ADPKD in potential donors. Renal imaging may not exclude ADPKD particularly in younger donors and molecular genetic testing is advised. We report the largest series to date evaluating the role of genetic testing for ADPKD in LRKD assessment...
May 2015: Transplantation
Hester Happé, Dorien J M Peters
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in PKD1 or PKD2, which encode polycystin-1 and polycystin-2, respectively. Rodent models are available to study the pathogenesis of polycystic kidney disease (PKD) and for preclinical testing of potential therapies-either genetically engineered models carrying mutations in Pkd1 or Pkd2 or models of renal cystic disease that do not have mutations in these genes. The models are characterized by age at onset of disease, rate of disease progression, the affected nephron segment, the number of affected nephrons, synchronized or unsynchronized cyst formation and the extent of fibrosis and inflammation...
October 2014: Nature Reviews. Nephrology
Niek F Casteleijn, Folkert W Visser, Joost P H Drenth, Tom J G Gevers, Gerbrand J Groen, Marie C Hogan, Ron T Gansevoort
Chronic pain, defined as pain existing for >4-6 weeks, affects >60% of patients with autosomal-dominant polycystic disease (ADPKD). It can have various causes, indirectly or directly related to the increase in kidney and liver volume in these patients. Chronic pain in ADPKD patients is often severe, impacting physical activity and social relationships, and frequently difficult to manage. This review provides an overview of pathophysiological mechanisms that can lead to pain and discusses the sensory innervation of the kidneys and the upper abdominal organs, including the liver...
September 2014: Nephrology, Dialysis, Transplantation
Elisabet Ars, Carmen Bernis, Gloria Fraga, Víctor Martínez, Judith Martins, Alberto Ortiz, José Carlos Rodríguez-Pérez, Laia Sans, Roser Torra
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent cause of genetic renal disease and accounts for 6-10% of patients on renal replacement therapy (RRT). Very few prospective, randomized trials or clinical studies address the diagnosis and management of this relatively frequent disorder. No clinical guidelines are available to date. This is a consensus statement presenting the recommendations of the Spanish Working Group on Inherited Kidney Diseases, which were agreed to following a literature search and discussions...
September 2014: Nephrology, Dialysis, Transplantation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"